Daniel M. Gitner, a partner at Lankler Siffert & Wohl, and Patrick P. Garlinger, an associate at the firm, analyze the Second Circuit's recent holding in 'United States v. Caronia' and conclude that in response to that decision the government may undertake an even more stringent and aggressive approach to investigating potential violations of the misbranding provisions of the Food, Drug, and Cosmetic Act.
Off-Label Drug Promotion and the First Amendment
New York Law Journal
February 1, 2013
This content is now available at LexisNexis®.
The ALM® and LexisNexis® Content Alliance
LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM’s legal news publications. LexisNexis® customers will be able to access and use ALM’s content by subscribing to the LexisNexis® services via lexis.com® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM’s other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.
ALM’s content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.
If you are not currently a LexisNexis subscriber, contact 1-800-227-4908 to find out more or click here to have a customer representative contact you directly.